After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
On Friday, July 29, investors will get quarterly results from Anheuser-Busch Inbev and the first estimate of second quarter GDP.
Merck (MRK) stock is slipping this morning as the company expects to post fiscal 2016 second quarter results before tomorrow's market open.
It's too cheap for a biotech giant with years of patent protection for key products and great cash flow.
Merck (MRK) announced that its experimental Ebola vaccine V920 has been put under 'accelerated' review in the U.S. and the EU.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.